These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35335004)

  • 1. Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects.
    Gianchecchi E; Cianchi V; Torelli A; Montomoli E
    Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35335004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the absence or intermittent YF vaccination the major contributor to its persistent outbreaks in eastern Africa?
    Baba MM; Ikusemoran M
    Biochem Biophys Res Commun; 2017 Oct; 492(4):548-557. PubMed ID: 28109882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow fever: the recurring plague.
    Tomori O
    Crit Rev Clin Lab Sci; 2004; 41(4):391-427. PubMed ID: 15487593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.
    Bifani AM; Ong EZ; de Alwis R
    Curr Treat Options Infect Dis; 2020; 12(4):398-409. PubMed ID: 33173445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.
    Bifani AM; Ong EZ; de Alwis R
    Curr Treat Options Infect Dis; 2020; 12(3):349-360. PubMed ID: 32837338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the large-scale yellow fever outbreak in Luanda, Angola, and the impact of vaccination.
    Zhao S; Stone L; Gao D; He D
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006158. PubMed ID: 29338001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: A desk review of global data sources.
    Adrien N; Hyde TB; Gacic-Dobo M; Hombach J; Krishnaswamy A; Lambach P
    Vaccine; 2019 Jul; 37(32):4511-4517. PubMed ID: 31266670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yellow fever control: current epidemiology and vaccination strategies.
    Chen LH; Wilson ME
    Trop Dis Travel Med Vaccines; 2020; 6():1. PubMed ID: 31938550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, drivers and global health implications of the 2019/2020 yellow fever sporadic outbreaks in Sub-Saharan Africa.
    Uchenna Emeribe A; Nasir Abdullahi I; O R Ajagbe O; Egede Ugwu C; Oloche Onoja S; Dahiru Abubakar S; Modesta Umeozuru C; Sunday Animasaun O; Omoruyi Omosigho P; Mukhtar Danmusa U; Alhaji Baba Mallam M; Saidu Aminu M; Yahaya H; Oyewusi S
    Pathog Dis; 2021 Apr; 79(4):. PubMed ID: 33739369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of yellow fever in persons traveling to the tropics.
    Monath TP; Cetron MS
    Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global Risk and Elimination of Yellow Fever Epidemics.
    Ndeffo-Mbah ML; Pandey A
    J Infect Dis; 2020 Jun; 221(12):2026-2034. PubMed ID: 31545372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The global burden of yellow fever.
    Gaythorpe KA; Hamlet A; Jean K; Garkauskas Ramos D; Cibrelus L; Garske T; Ferguson N
    Elife; 2021 Mar; 10():. PubMed ID: 33722340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of yellow fever on the developing world.
    Tomori O
    Adv Virus Res; 1999; 53():5-34. PubMed ID: 10582093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Assessment of Yellow Fever and Yellow Fever Vaccine.
    Lefeuvre A; Marianneau P; Deubel V
    Curr Infect Dis Rep; 2004 Apr; 6(2):96-104. PubMed ID: 15023271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials.
    Dia M; Bob NS; Talla C; Dupressoir A; Escadafal C; Thiam MS; Diallo A; Ndiaye O; Heraud JM; Faye O; Sall AA; Faye O; Fall G
    J Med Virol; 2023 Apr; 95(4):e28700. PubMed ID: 36951314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological description of and response to a large yellow fever outbreak in Edo state Nigeria, September 2018 - January 2019.
    Nwachukwu William E; Oladejo J; Ofoegbunam CM; Anueyiagu C; Dogunro F; Etiki SO; Dachung BI; Obiekea C; Aderoju B; Akanbi K; Adeyemi IT; Famokun GA; Emelife O; Osamwonyi IW; Ochu CL; Abiode A; Ireye F; Chukwuji M; Ipadeola O; Saiki M; Okudo I; Nwodo D; Oteri JA; Ilori E; Mba N; Ihekweazu C
    BMC Public Health; 2022 Aug; 22(1):1644. PubMed ID: 36042438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of YF-neutralizing antibodies in vulnerable populations of Brazil: A warning for epidemiological surveillance and the potential risks for future outbreaks.
    Stoffella-Dutra AG; Silva de Oliveira J; Barbosa Costa G; Geessien Kroon E; Santos Abrahão J; Desiree LaBeaud A; Paiva Drumond B; Bretas de Oliveira D; de Souza Trindade G
    Vaccine; 2020 Sep; 38(42):6592-6599. PubMed ID: 32788140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever: a reemerging threat.
    Gardner CL; Ryman KD
    Clin Lab Med; 2010 Mar; 30(1):237-60. PubMed ID: 20513550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.